Neurocrine Biosciences
NBIX
#1397
Rank
A$23.74 B
Marketcap
A$233.64
Share price
0.92%
Change (1 day)
22.76%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2026 (TTM): A$1.19 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are A$3.10 Billion. In 2025 the company made an earning of A$0.90 Billion, an increase over its 2024 earnings that were of A$0.86 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) A$1.19 B32.23%
2025 A$0.90 B3.9%
2024 A$0.86 B96.41%
2023 A$0.44 B41.13%
2022 A$0.31 B73.74%
2021 A$0.18 B-8.82%
2020 A$0.19 B77.78%
2019 A$0.11 B49.83%
2018 A$74.19 M-142.57%
2017 -A$0.18 Billion-14.73%
2016 -A$0.21 Billion53.15%
2015 -A$0.14 Billion46.25%
2014 -A$91.26 Million29.66%
2013 -A$70.38 Million-3530.8%
2012 A$2.05 M-95.73%
2011 A$48.05 M
2009 -A$67.56 Million-45.38%
2008 -A$0.13 Billion-58.87%
2007 -A$0.31 Billion87.3%
2006 -A$0.17 Billion351.97%
2005 -A$35.52 Million-52.09%
2004 -A$74.15 Million-10.98%
2003 -A$83.29 Million
2001 -A$62.17 Million
1999 -A$28.04 Million108.32%
1998 -A$13.46 Million
1996 A$4.1 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
A$15.00 B 1,225.86%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$8.46 B 648.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$44.09 B 3,796.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$0.11 B-90.23%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-A$59.17 Million-105.23%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$0.16 B-85.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-A$8.85 Million-100.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.40 B 112.21%๐Ÿ‡ฌ๐Ÿ‡ง UK